Premium
TREATMENT OF ENDOMETRIOSIS: A STUDY OF MEDICAL MANAGEMENT
Author(s) -
Noble A. D.,
Letchworth A. T.
Publication year - 1980
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1980.tb04607.x
Subject(s) - danazol , endometriosis , medicine , norethynodrel , mestranol , medical treatment , hormone , disease , medical therapy , fibrosis , fertility , surgery , gynecology , population , family planning , intensive care medicine , research methodology , environmental health
Summary Fifty patients with endometriosis were treated with hormones: 27 with danazol and 23 with Enavid (mestranol 75 μg and norethynodrel 5 mg). Side effects were more common and potentially more serious in the group treated with Enavid. Fewer women completed treatment with Enavid and their physical signs showed little improvement. Danazol was better tolerated and the results of treatment, as judged by improvement of symptoms or signs and in future fertility rates, were superior to those recorded in the Enavid treated group. Patients with large endometriotic cysts or severe fibrosis did not benefit from medical treatment. Danazol treatment appeared helpful for women who had mild or moderate endometriotic disease. It may be used alone or as a complimentary treatment after conservative surgical operations.